SC Liver Research Consortium, LLC Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2014
NCT02214420
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

SC Liver Research Consortium, LLC

Active Ingredients

Drugs in Phase 4 Trials (3)

ribavirin (virazole) (1 trial)

simeprevir (olysio) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Drugs in Phase 2 Trials (1)

regorafenib (stivarga) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Hepatitis (Phase 4)

Hepatitis C (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4